These data suggested that TRIM25 decreased the stability of BRD7 protein through the ubiquitin-proteasome pathway, thereby activating the YB1/Bcl-2 transcription axis and resulting in the malignant progression and PTX resistance of breast cancer. Here, BCL2 is linked to breast carcinoma.